A robot can hold a squash, pumpkin or melon in one hand, while it is peeled by the other

Devices that let people with paralysis walk and talk are rapidly improving. Some see a future in which we alter memories and download skills – but major challenges remain

After their initial training phase, AI algorithms can’t update and learn from new data, meaning tech companies have to keep training new models from scratch

NASA’s Valkyrie is undergoing tests to understand what it would take to get a humanoid robot onto offshore facilities or into space. New Scientist's James Woodford took the controls to see what it is capable of

If artificial intelligence chatbots are fine-tuned to improve their responses using human feedback, they can become more likely to give deceptive answers that seem right but aren’t

Google DeepMind claims its AlphaChip AI method can deliver “superhuman” chip designs that are already used in its data centres – but independent experts say public proof is lacking

It is thought that humans can only maintain relationships with around 150 people, a figure known as Dunbar's number, but it seems that AI models can outstrip this and reach consensus in far bigger groups

A simulator for the process of scientific discovery shows that AI models still fall short of human scientists and engineers in coming up with hypotheses and carrying out experiments on their own

A type of mathematical problem that was previously impossible to solve can now be successfully analysed with artificial intelligence

One day, doctors might be able to 3D print copies of your organs in order to test a variety of drugs, thanks to a new technique that uses light and sound for rapid printing

Video Friday is your weekly selection of awesome robotics videos, collected by your friends at IEEE Spectrum robotics. We also post a weekly calendar of upcoming robotics events for the next few months. Please send us your events for inclusion.

Humanoids 2024: 22–24 November 2024, NANCY, FRANCE

Enjoy today’s videos!

Swiss-Mile’s robot (which is really any robot that meets the hardware requirement to run their software) is faster than “most humans.” So what does that mean, exactly?

The winner here is Riccardo Rancan, who doesn’t look like he was trying especially hard—he’s the world champion in high-speed urban orienteering, which is a sport that I did not know existed but sounds pretty awesome.

[ Swiss-Mile ]

Thanks, Marko!

Oh good, we’re building giant fruit fly robots now.

But seriously, this is useful and important research because understanding the relationship between a nervous system and a bunch of legs can only be helpful as we ask more and more of legged robotic platforms.

[ Paper ]

Thanks, Clarus!

Watching humanoids get up off the ground will never not be fascinating.

[ Fourier ]

The Kepler Forerunner K2 represents the Gen 5.0 robot model, showcasing a seamless integration of the humanoid robot’s cerebral, cerebellar, and high-load body functions.

[ Kepler ]

Diffusion Forcing combines the strength of full-sequence diffusion models (like SORA) and next-token models (like LLMs), acting as either or a mix at sampling time for different applications without retraining.

[ MIT ]

Testing robot arms for space is no joke.

[ GITAI ]

Welcome to the Modular Robotics Lab (ModLab), a subgroup of the GRASP Lab and the Mechanical Engineering and Applied Mechanics Department at the University of Pennsylvania under the supervision of Prof. Mark Yim.

[ ModLab ]

This is much more amusing than it has any right to be.

[ Westwood Robotics ]

Let’s go for a walk with Adam at IROS’24!

[ PNDbotics ]

From Reachy 1 in 2023 to our newly launched Reachy 2, our grippers have been designed to enhance precision and dexterity in object manipulation. Some of the models featured in the video are prototypes used for various tests, showing the innovation behind the scenes.

[ Pollen ]

I’m not sure how else you’d efficiently spray the tops of trees? Drones seem like a no-brainer here.

[ SUIND ]

Presented at ICRA40 in Rotterdam, we show the challenges faced by mobile manipulation platforms in the field. We at CSIRO Robotics are working steadily towards a collaborative approach to tackle such challenging technical problems.

[ CSIRO ]

ABB is best known for arms, but it looks like they’re exploring AMRs (autonomous mobile robots) for warehouse operations now.

[ ABB ]

Howie Choset, Lu Li, and Victoria Webster-Wood of the Manufacturing Futures Institute explain their work to create specialized sensors that allow robots to “feel” the world around them.

[ CMU ]

Columbia Engineering Lecture Series in AI: “How Could Machines Reach Human-Level Intelligence?” by Yann LeCun.

Animals and humans understand the physical world, have common sense, possess a persistent memory, can reason, and can plan complex sequences of subgoals and actions. These essential characteristics of intelligent behavior are still beyond the capabilities of today’s most powerful AI architectures, such as Auto-Regressive LLMs.
I will present a cognitive architecture that may constitute a path towards human-level AI. The centerpiece of the architecture is a predictive world model that allows the system to predict the consequences of its actions. and to plan sequences of actions that that fulfill a set of objectives. The objectives may include guardrails that guarantee the system’s controllability and safety. The world model employs a Joint Embedding Predictive Architecture (JEPA) trained with self-supervised learning, largely by observation.

[ Columbia ]

People keep predicting that each wave of new technology will mean humans can put their feet up. It hasn't happened yet. Some economists and anthropologists who study the subject say even with the arrival of artificial intelligence, humans will remain integral to making the world go round.

If rumours are true and this one should be, I started it, we have a special edition of the Weekend show where we talk about the evolution of the role of the CIO with two incredible CIOs as the CIO Association of Canada turns 20. Don’t miss it.  MUSIC UP Can HP make you love […]

The post Hashtag Trending Mar.1- HP debacle; Humanoid robots closer to hitting our workplaces; Apple blew $10 billion on the electric car before pulling the plug first appeared on ITBusiness.ca.

New research led by scientists from the University of Pennsylvania, Karolinska Institute and Linköping University provides a landscape view of the human sense of touch.

The post Neuroscientists Identify 16 Neuronal Types Involved in Human Sense of Touch appeared first on Sci.News: Breaking Science News.

The identification of a new hominin group called Denisovans was one of the most exciting discoveries in human evolution in the last decade.

The post Several Denisovan Populations Introgressed into Modern Humans Multiple Times: Study appeared first on Sci.News: Breaking Science News.

A bird flu virus that has been circulating in dairy cattle for months has now been found in a pig in the US for the first time, raising the risk of the virus evolving to become more dangerous to people

Human bird flu has hospitalized a Canadian teenager at British Columbia Children’s Hospital. He is the first person in Canada to test positive for the bird flu virus. The B.C. teen likely acquired the virus from exposure to a bird or animal. B.C. Health said the infection is a rare... Continue Reading

Humane first reported overheating problems with the portable charger in June.

Kannada superstar Shivarajkumar, who is awaiting the release of his much-anticipated film ‘Bhairathi Ranagal’, has said that he is set to undergo a surgery for his illness

Tentatively called D55, the film is produced by Sushmita Anbuchezian under the Gopuram Films banner

‘Jai Hanuman’, a sequel to ‘HanuMan’, will have Rishab Shetty in the lead and the movie will be produced by Mythri Movie Makers

Hello gentle readers, and welcome to the SwitchArcade Round-Up for August 30th, 2024. In today’s article, we have a handful …

Continue reading "SwitchArcade Round-Up: ‘Umamusume: Pretty Derby’, ‘Super Dark Deception’, Plus Today’s Other Releases and Sales"

Combining DNA analysis, archeological techniques, and historical records overturns some assumptions of the people of Pompeii.

The 3.2-million-year-old human ancestor known as Lucy rose to fame through an incredible combination of circumstances

<p>The US Food and Drug Administration (FDA) granted approval for two&nbsp;biosimilars, Formycon’s FYB202/Otulfi (ustekinumab-aauz) and Samsung Bioepis’ Soliris biosimilar, Epysqli (eculizumab-aagh), on 27 September and 22 July 2024, respectively. FYB202/Otulfi, a biosimilar referencing&nbsp;Johnson &amp; Johnson’s Stelara, while Epysqli is a biosimilar referencing Alexion’s Soliris.</p>

<p>The European Commission (EC) granted marketing authorization for<b>&nbsp;</b>three ustekinumab biosimilars<b>:&nbsp;</b>Samsung Bioepis’ Eksunbi on 12 September 2024; Formycon’s Fymskina, and Fresenius Kabi’s&nbsp;Otulfi on 25 September 2024.</p>

The decade following passage of FDAAA has been one of easing standards for drug approvals in the US, most notably with the advent of “breakthrough” designation created by FDASIA in 2012 and the 21st Century Cures Act in 2016.

Although, as of this writing, there is no nominee for FDA Commissioner, it appears to be safe to say that the current administration intends to accelerate the pace of deregulation, mostly through further lowering of approval requirements. In fact, some of the leading contenders for the position are on record as supporting a return to pre-Kefauver-Harris days, when drug efficacy was not even considered for approval.

Build a better mouse model, and pharma will beat a path to your door - no laws needed.

In this context, it is at least refreshing to read a proposal to increase efficacy standards. This comes from two bioethicists at McGill University, who make the somewhat-startling case for a higher degree of efficacy evaluation before a drug begins any testing in humans.

We contend that a lack of emphasis on evidence for the efficacy of drug candidates is all too common in decisions about whether an experimental medicine can be tested in humans. We call for infrastructure, resources and better methods to rigorously evaluate the clinical promise of new interventions before testing them on humans for the first time.

The author propose some sort of centralized clearinghouse to evaluate efficacy more rigorously. It is unclear what they envision this new multispecialty review body’s standards for green-lighting a drug to enter human testing. Instead they propose three questions:

• What is the likelihood that the drug will prove clinically useful?
• Assume the drug works in humans. What is the likelihood of observing the preclinical results?
• Assume the drug does not work in humans. What is the likelihood of observing the preclinical results?

These seem like reasonable questions, I suppose – and are likely questions that are already being asked of preclinical data. They certainly do not rise to the level of providing a clear standard for regulatory approval, though perhaps it’s a reasonable place to start.

The most obvious counterargument here is one that the authors curiously don’t pick up on at all: if we had the ability to accurately (or even semiaccurately) predict efficacy preclinically, pharma sponsors would already be doing it. The comment notes: “More-thorough assessments of clinical potential before trials begin could lower failure rates and drug-development costs.” And it’s hard not to agree: every pharmaceutical company would love to have even an incrementally-better sense of whether their early pipeline drugs will be shown to work as hoped.

The authors note

Commercial interests cannot be trusted to ensure that human trials are launched only when the case for clinical potential is robust. We believe that many FIH studies are launched on the basis of flimsy, underscrutinized evidence.

However, they do not produce any evidence that industry is in any way deliberately underperforming their preclinical work, merely that preclinical efficacy is often difficult to reproduce and is poorly correlated with drug performance in humans.

Pharmaceutical companies have many times more candidate compounds than they can possibly afford to put into clinical trials. Figuring out how to lower failure rates – or at least the total cost of failure - is a prominent industry obsession, and efficacy remains the largest source of late-stage trial failure. This quest to “fail faster” has resulted in larger and more expensive phase 2 trials, and even to increased efficacy testing in some phase 1 trials. And we do this not because of regulatory pressure, but because of hopes that these efforts will save overall costs. So it seems beyond probable that companies would immediately invest more in preclinical efficacy testing, if such testing could be shown to have any real predictive power. But generally speaking, it does not.

As a general rule, we don’t need regulations that are firmly aligned with market incentives, we need regulations if and when we think those incentives might run counter to the general good. In this case, there are already incredibly strong market incentives to improve preclinical assessments. Where companies have attempted to do something with limited success, it would seem quixotic to think that regulatory fiat will accomplish more.

(One further point. The authors try to link the need for preclinical efficacy testing to the 2016 Bial tragedy. This seems incredibly tenuous: the authors speculate that perhaps trial participants would not have been harmed and killed if Bial had been required to produce more evidence of BIA102474’s clinical efficacy before embarking on their phase 1 trials. But that would have been entirely coincidental in this case: if the drug had in fact more evidence of therapeutic promise, the tragedy still would have happened, because it had nothing at all to do with the drug’s efficacy.

This is to some extent a minor nitpick, since the argument in favor of earlier efficacy testing does not depend on a link to Bial. However, I bring it up because a) the authors dedicate the first four paragraphs of their comment to the link, and b) there appears to be a minor trend of using the death and injuries of that trial to justify an array of otherwise-unrelated initiatives. This seems like a trend we should discourage.)

[Update 2/23: I posted this last night, not realizing that only a few hours earlier, John LaMattina had published on this same article. His take is similar to mine, in that he is suspicious of the idea that pharmaceutical companies would knowingly push ineffective drugs up their pipeline.]

Kimmelman, J., & Federico, C. (2017). Consider drug efficacy before first-in-human trials Nature, 542 (7639), 25-27 DOI: 10.1038/542025a

A person has tested positive in British Columbia, Canadian health officials said, though the results must be sent to another lab for confirmation.

As winter arrives and daylight hours decrease, it gets easier to hit the snooze button and stay in bed. It turns out that there’s a scientific reason behind this phenomenon that helps to explain why people struggle to adjust their internal clocks—also known as circadian rhythm or sleep-wake cycle—when the weather turns colder.

OTTAWA - Canada has detected its first presumptive case of H5 bird flu in a person, a teenager in the western province of British Columbia, health officials said on Saturday (Nov 9). The teenager likely caught the virus from a bird or animal and was receiving care at a children's hospital, the province said in a statement. The province said it was investigating the source of exposure and identifying the teenager's contacts. The risk to the public remains low, Canada's Health Minister Mark Holland said in posting on X. "This is a rare event," British Columbia Health Officer Bonnie Henry said in a statement. "We are conducting a thorough investigation to fully understand the source of exposure here in B.C." H5 bird flu is widespread in wild birds worldwide and is causing outbreaks in poultry and US dairy cows, with several recent human cases in US dairy and poultry workers. There has been no evidence of person-to-person spread so far. But if that were to happen, a pandemic could unfold, scientists have said.

TORONTO — A teenager is in critical condition in a British Columbia children's hospital, sick with Canada's first presumptive human case of avian influenza. "This was a healthy teenager prior to this, so no underlying conditions," said provincial health officer Bonnie Henry in a news conference on Tuesday (Nov 12). "It just reminds us that in young people this is a virus that can progress and cause quite severe illness and the deterioration that I mentioned was quite rapid." British Columbia health officials said on Saturday the province had detected Canada's first human case of H5 bird flu in a teenager.

WASHINGTON — Donald Trump is expected to take a slew of executive actions on his first day as president to ramp up immigration enforcement and roll back signature Biden legal entry programs, a sweeping effort that will be led by incoming "border czar" Tom Homan and other Republican immigration hardliners, three sources familiar with the matter told Reuters. The executive actions would give federal immigration officers more latitude to arrest people with no criminal records, surge troops to the US-Mexico border and restart construction of the border wall, the sources said. Homan, who served as acting director of US Immigration and Customs Enforcement from 2017-2018 under Trump, will bring a deep understanding of the US immigration system after a four-decade career that took him from a frontline Border Patrol agent to head of the agency that arrests and deports immigrants in the US illegally.

Pakistan concern that freedom of expression be balanced with respect for religion as "we are not as advanced as you are" in terms of respect for freedom of religion and could not always control the reactions of sometimes ignorant crowds.

Dec 15, 2017

To ministers and heads of state, he was a sought-after adviser, pointing the way toward reforms that boosted farm yields, educational standards, and economic prosperity. To the scientific community, he was an unstinting champion of innovation and rigorous evidence. To his students, he was a passionate teacher and mentor. To thousands of his fans on social media, he was a fount of insight, optimism, and good humor. To us, he was a dear friend and extraordinary colleague.

Dec 18, 2017

Our colleague Calestous Juma—who passed away on December 15 at age 64 after a long illness—was a pioneering, prolific, and influential scholar/practitioner in science and technology policy for sustainable well-being. He joined Harvard Kennedy School (HKS) in 1999 as Director of the Science, Technology, and Innovation Project (a joint venture of the Belfer Center for Science and International Affairs and the Center for International Development) and became Professor of the Practice of International Development in 2002, a position in which he maintained his exceptional productivity and engagement with policy, despite illness, up to the time of his death.

Dec 19, 2017

Celebrating the life and achievements of Professor Calestous Juma.

Jun 28, 2024

Ensuring that space remains a domain for peaceful exploration and mutual benefit rather than a new frontier for conflict will significantly depend on the global community's ability to navigate the complex interplay of technological advancements, regulatory frameworks, economic opportunities, and geopolitical challenges. 

This paper was written for the final assignment of IGA-250, a Harvard Kennedy School course on emerging technology: security, strategy, and risk.

Apr 9, 2024

On April 2, the study group met for the second time to evaluate the role of international humanitarian groups in shaping political and social outcomes in Africa. The group examined how these organizations deal with emergencies, crises, and conflict situations across the continent, and scrutinized their influence on policy decisions and discuss the potential benefits and drawbacks of their involvement. Discussions covered the expanding influence of organizations like the United Nations High Commissioner for Refugees (UNHCR), Médecins Sans Frontières (Doctors Without Borders), and the International Rescue Committee (ICR). The study group counted with the presence of external expert guest Professor Sabs K. Quereshi, a senior-level leader with 17+ years of experience in global health, gender equality, health policy and equity, national security, humanitarian response, and government and multilateral affairs sectors in the U.S., with the UN, and worldwide.

Human Resources

Watch these doctors enjoy a taste of their own medicine #FindYourPark

As Israel continues to block lifesaving humanitarian aid from entering northern Gaza, humanitarian organizations are describing its siege as “apocalyptic” and warning of mass Palestinian starvation and death. “The situation is absolutely desperate,” says Rachael Cummings of the aid group Save the Children International. Cummings joins us from Deir al-Balah in central Gaza, where aid organizations have been halted from entering the north. She responds to news of Israel’s bombing of a polio vaccination center in an area that had been marked for an official humanitarian pause, and the Knesset’s vote to ban the U.N. relief agency UNRWA.

Top U.N. officials are again warning that the entire Palestinian population in north Gaza is “at imminent risk of dying from disease, famine and violence.” At least 1,800 Palestinians have been killed, many of them children, since October, when Israel imposed a draconian siege and began an intensified campaign of ethnic cleansing on northern Gaza. Jan Egeland of the Norwegian Refugee Council recently spent several days in Gaza. He describes what he saw as “devastation beyond belief,” as Palestinians face “the most intense and most indiscriminate bombardment anywhere in the world in recent memory,” coupled with the utter depletion of aid. Egeland pleads for the United States, the largest supplier of military funding and equipment to Israel, to condition its weapons to Israel, enforce the provision of aid and commit to ending Israel’s assault. “It’s not in Israel’s interest to destroy its neighborhood in Gaza and in Lebanon. It will create new generations of hatred,” Egeland says.

Rod-shaped fragments of RNA called “obelisks” were discovered in gut and mouth bacteria for the first time

After the successful collaboration PUMA has introduced its sneakers into the main product line...

The post PUMA Suede XL Sneakers first appeared on peopleofdesign.

A type of mathematical problem that was previously impossible to solve can now be successfully analysed with artificial intelligence

A bird flu virus that has been circulating in dairy cattle for months has now been found in a pig in the US for the first time, raising the risk of the virus evolving to become more dangerous to people

One day, doctors might be able to 3D print copies of your organs in order to test a variety of drugs, thanks to a new technique that uses light and sound for rapid printing

Most assessments of global warming use 1850-1900 as a baseline, but researchers have now established a new pre-industrial reference by using Antarctic ice cores to estimate the average temperature before 1700

"All generalizations are dangerous, even this one."